Who’s on your bench? The five people every high performer needs
Your clinical career is shaped not only by what you know, but by who helps you navigate what comes next. Join us for the final episode in our mini-series exploring non-clinical skills that can help you thrive in your clinical career. Today we explore how to develop the right team around you to support your […]
ASH25 round-up: Late-breakers in multiple myeloma and CLL/SLL
Discover the practice-changing data shaping the future of myeloma, chronic lymphocytic leukemia and small lymphocytic lymphoma. Our ASH25 coverage highlights the pivotal Majestec-3 results, emerging CAR T-cell innovations, and the landmark BRUIN CLL-313 trial poised to redefine first-line therapy. With expert commentary from Prof. Meletios-Athanasios Dimopoulos, this in-depth analysis uncovers what these breakthroughs mean for clinical practice.
Acute lymphoblastic leukaemia: Immunotherapy impact across the age spectrum
In this Haematology Horizons practice pearl, Dr Hannah Levavi explores how CAR-T therapy is transforming adult ALL care—especially for older or unfit patients previously ineligible for transplant. She highlights early-use strategies, reduced-intensity induction regimens and promising developments like allogeneic CAR-T and novel antigen targets.
EBMT 2026: Highlights from the 52nd Annual Meeting
In proud collaboration with EBMT, we have captured the highlights from the recent 52nd Annual Meeting, EBMT 2026. Below, hear from Dr Anna Sureda, President of EBMT, Dr Rafael Duarte, Congress President, and other world-leading experts sharing some of the most important research in transplant and cellular therapies. Dr Anna Sureda • President, EBMT […]
01. Who’s on your bench? The five people every high performer needs
02. ASH25 round-up: Late-breakers in multiple myeloma and CLL/SLL
03. Acute lymphoblastic leukaemia: Immunotherapy impact across the age spectrum
04. EBMT 2026: Highlights from the 52nd Annual Meeting
Your clinical career is shaped not only by what you know, but by who helps you navigate what comes next. Join us for the final episode in our mini-series exploring non-clinical skills that can help you thrive in your clinical ...
We often focus on clinical excellence, but spend less time developing broader skills that could help us better lead with purpose and build more fulfilling, impactful careers. In this episode, part of a mini-series in partnership with LEADderm, Dr Jennifer Soung and Denise Mann explore how clinicians can engage with the media to educate, empower and extend their impact beyond the clinic.
Whether you’re working in an agency, in a clinical role, or in academia, many healthcare professionals wonder what lies behind the doors of the pharmaceutical industry. In this episode, Gina is joined by Sian Kneller, Director of Global Content Design at GSK and Founder of The Agency Advantage, to unpack exactly what it takes to make the leap. With over 20 years’ experience, from medical writer to leading global medical affairs strategy, Sian now helps others make a successful move into pharma. In this episode she shares what the transition really looks like, which transferable skills matter most, and how you can stand out in a competitive field.
Isatuximab is a CD38-receptor targeted monoclonal antibody approved as a combination therapy for the treatment of RRMM in patients who have received 1 to 3 lines of prior therapy.
Want to be featured in touchReviews in Oncology & Haematology?
Share your knowledge, influence clinical practices and enhance patient care in Hematology today!
- Peer-reviewed, free-to-access
- Accepting reviews, research and editorials
- No article processing fees
- Digital features and plain language summaries
- Multichannel content distribution for maximum visibility
A leading expert on sleep and shift work, Grace explores how disrupted sleep affects physician health in both the short and long term, as well as its impact on safety and performance. We also discuss what this means for patient outcomes and share practical strategies to manage sleep loss.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
In our latest episode, we delve into the world of space medicine to explore how drug crystallization in microgravity could revolutionize biologic drug administration. Joining us is Dr Katie King, CEO of BioOrbit, to discuss the science, challenges, and technological advancements that could make space-based drug production a reality.
Few alliances have impacted patient care as significantly as the Myeloproliferative Neoplasms Research Consortium (MPN-RC). Established in 2006, the MPN-RC is an international group dedicated to advancing research and developing innovative treatment strategies for myeloproliferative neoplasms (MPNs). In this episode, we speak with John Mascarenhas, MD, about the coalition's founding, operational mechanics and how their efforts have led to paradigm-shifting therapies in the field.
“We are facing an exciting era of fast-paced drug development in acute myeloid leukaemia” writes Gianfranco Bittar and colleagues at Baylor College of Medicine, Houston, TX, USA, in a review published in touchREVIEWS in Oncology & Haematology. In 2020, there were ...
Histone-lysine N-methyltransferase 2A rearrangements (KMT2Ar) and mutant nucleophosmin 1 (mNPM1) occur in approximately 5–10% and 30% of patients with acute myeloid leukaemia (AML), respectively.1,2 Both mutations are associated with the founding events in the development of leukaemia.1 In particular, KMT2Ar functions ...
Frontline treatment with azacitidine plus venetoclax (AZA/VEN) significantly improved remission rates and survival duration for older, frail and high-risk patients with acute myeloid leukaemia (AML) in the pivotal VIALE-A trial.1 The combination is approved for use in this setting,2 ...
Editorial Board
Introducing the Expert Faculty of touchHEMATOLOGY, who support our mission to advance medical knowledge and practice by ensuring the integrity, relevance, and impact of the content we publish. Together, we strive to foster a vibrant academic community and contribute to the continuous improvement of healthcare worldwide.
Jorge Cortes
Georgia Cancer Center, Augusta University, Augusta, GA, USA
Leukaemia
Martin Hutchings
Advisory Board Member
Martin Hutchings
Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Lymphoma
Biography
Dr Hutchings has been the Chairman of the EORTC lymphoma group since 2013 and a faculty member for the EHA Clinical Research Training in Haematology programme.
He is a member of the scientific committee for the European Haematology Association National and has been principal investigator or sub-investigator for >25 solid tumour and haematology phase I trials and >20 lymphoma and myeloma phase II and phase III trials. He is the national principal investigator for three mantle cell lymphoma trials (one ongoing and two planned) and three Hodgkin lymphoma trials.
He is the co-author of the international response criteria and guidelines for the use of imaging in lymphoma and the European society of Medical Oncology (ESMO) guidelines for Hodgkin lymphoma and ’ultra high-risk’ lymphomas.
Jorge Cortes
Advisory Board Member
Pinkal Desai
Advisory Board Member
Pinkal Desai
Weill Cornell Medical College, New York, NY, USA
Leukaemia
Biography
Pinkal Desai MD, MPH is an Assistant Professor of Medicine at Weill Cornell Medical College and Assistant Attending Physician at the New York-Presbyterian Hospital.
After obtaining her MBBS at Byramjeejeebhoy Medical College in India in 2005, Dr. Desai obtained an MPH at the University of Alabama at Birmingham School of Public Health. Following her residency at Wayne State University, Detroit Medical Center, she underwent fellowship training in Hematology-Medical Oncology at Providence Hospital Medical Center, serving as Chief Fellow from 2012-2013. Dr. Desai was recruited to serve in our Leukemia Program to develop a clinical practice devoted to leukemia, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). She will be developing clinical and translational research protocols and projects in the areas of leukemia, MDS and MPN.
Dr. Desai is published in Cancer Epidemiology Biomarkers Prevention and International Journal of Molecular Epidemiology and Genetics. She is the lead author and co-author on numerous WHI (Women’s Health Initiative) paper proposals and has presented abstracts at national meetings. She is a member of American Society of Hematology (ASH) and American Society of Clinical Oncology (ASCO) and has served on the ASCO University Committee.
Martin Hutchings
Advisory Board Member
John Mascarenhas
Faculty member
John Mascarenhas
New York, USA
Myelodysplastic Syndrome
Biography
Dr John Mascarenhas is a Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute in New York City. Dr Mascarenhas is the Director of Center of Excellence in Blood Cancers and Myeloid Disorders, Director of the Adult Leukemia Program, and Leader of Clinical Research within the Myeloproliferative Disorders Program at Mount Sinai. As a clinical investigator in malignant hematology with a focus in translational research involving MPNs, he is primarily responsible for the clinical trials portion of the Myeloproliferative Disorders Program at ISMMS. Dr Mascarenhas is also the Principal Investigator (PI) of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Neoplasms Research Consortium (MPN-RC). He has served as PI or Study Chair of multiple investigator-initiated and industry-sponsored early and late phase clinical trials evaluating innovative approaches to the treatment of MPNs and secondary acute leukemia.
Pinkal Desai
Advisory Board Member
Jorge Cortes
Advisory Board Member
touchHEMATOLOGY
Register Now!
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
- Save your progress for video
- Keep track of your CME credits
- Add personalised learning notes
- Receive updates from course leaders and faculty
- Be the first to hear about new and exciting interactive learning opportunities
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
